% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lucio:844248,
author = {Lucio, David and Martínez-Ohárriz, María Cristina and
González-Navarro, Carlos J. and Navarro-Herrera, David and
González-Gaitano, Gustavo and Radulescu, Aurel and Irache,
Juan M.},
title = {{C}oencapsulation of cyclodextrins into poly(anhydride)
nanoparticles to improve the oral administration of
glibenclamide. {A} screening on {C}. elegans},
journal = {Colloids and surfaces / B},
volume = {163},
issn = {0927-7765},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {FZJ-2018-01689},
pages = {64 - 72},
year = {2018},
abstract = {This work describes the feasibility of poly(anhydride)
nanoparticles as carriers for the oral administration of
glibenclamide (GB) as well as the in vivo evaluation of
their hypolipidemic effect in a C. elegans model. For this
purpose, and in order to increase the GB payload, the drug
was encapsulated in nanoparticles in presence of
cyclodextrins (either βCD or HPβCD). The optimized
nanoparticles displayed a size of about 220 nm and a
negative zeta potential (−40 mV), with a drug loading up
to 52 μg/mg. Small-angle neutron scattering studies
suggested an internal fractal-like structure, based on the
repetition of spherical blocks of polymeric units (about
5 nm) grouped to form the nanoparticle. X-ray diffraction
study confirmed the absence of crystalline GB molecules due
to its dispersion into the nanoparticles, either entrapped
in the polymer chains and/or included into cyclodextrin
cavities. GB-loaded nanoparticles induced a significant
reduction in the fat content of C. elegans. This
hypolipidemic effect was slightly higher for the
nanoparticles prepared with coencapsulated HPβCD $(8.2\%)$
than for those prepared with βCD $(7.9\%)$ or in the
absence of cyclodextrins $(7.0\%).$ In summary, the
coencapsulation of cyclodextrins into poly(anhydride)
nanoparticles could be an interesting strategy to develop
new oral formulations of glibenclamide.},
cin = {JCNS (München) ; Jülich Centre for Neutron Science JCNS
(München) ; JCNS-FRM-II / Neutronenstreuung ; JCNS-1},
ddc = {540},
cid = {I:(DE-Juel1)JCNS-FRM-II-20110218 /
I:(DE-Juel1)JCNS-1-20110106},
pnm = {6G15 - FRM II / MLZ (POF3-6G15) / 6G4 - Jülich Centre for
Neutron Research (JCNS) (POF3-623)},
pid = {G:(DE-HGF)POF3-6G15 / G:(DE-HGF)POF3-6G4},
experiment = {EXP:(DE-MLZ)KWS2-20140101},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29277019},
UT = {WOS:000427217300008},
doi = {10.1016/j.colsurfb.2017.12.038},
url = {https://juser.fz-juelich.de/record/844248},
}